Updates are available Correction dated 2021-09-21

Article History

Received: 11 May 2021

Accepted: 9 July 2021

First Online: 30 August 2021

Change Date: 21 September 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00592-021-01802-x

Declarations

:

: Mitsuyoshi Takahara received research support fees from The Japan Diabetes Society and received an endowed chair funded by AstraZeneca K.K., Keiseikai Medical Corporation, Mitsubishi Tanabe Pharma Corp., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd. Ono Pharmaceutical Co., Ltd., and Taisho Toyama Pharmaceutical Co. Ltd. Naoto Katakami is a staff member of the endowed chair established by funds from Kowa Co., Ltd., and has received research funds from MSD and lecture fees from Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim, Daiichi Sankyo Inc., Eli Lilly, Kowa Pharmaceutical Co., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma Co., Novartis Pharmaceuticals, Novo Nordisk Pharma, Ono Pharmaceutical Co., Taisho Toyama Pharmaceutical Co., Takeda Pharmaceutical Co., and Sanofi-Aventis, and Shionogi & Co. Yasuaki Hayashino reports personal fees from Boehringer Ingelheim, Merck & Co., Inc., Kowa Pharmaceuticals, Inc., Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company, Ltd., and Teijin Pharma Limited, outside the submitted work. Rimei Nishimura has received honoraria from Astellas Pharma Inc., Nippon Boehringer Ingelheim Co. Ltd, Eli Lilly Japan K.K., Kissei Pharmaceutical Co. Ltd, Medtronic Japan Co. Ltd, MSD, Novartis Pharma K.K., Novo Nordisk Pharma Ltd, Sanofi K.K., Sumitomo Dainippon Pharma Co. Ltd., and Takeda Pharmaceutical Co. Ltd. He has also received a grant from the Japan Diabetes Foundation and Nippon Boehringer Ingelheim Co. Ltd. Hitoshi Shimano received research funds from and endowed chair or speaker fees from Kowa Company Ltd., Astellas Pharma Inc. and MSD. Naoko Tajima has received honoraria from Nippon Boehringer Ingelheim Co. Ltd and Takeda Pharmaceutical Co. Ltd. Yoshimitsu Yamasaki received research fees from AstraZeneca K.K., Taisho Toyama Pharmaceutical Co. Ltd., Eli Lilly, and Bayer Yakuhin, Ltd. The other authors have no conflicts of interest.

: This study was approved by the JDS Ethics Review Committee for Scientific Surveys and Studies and the Ethics Committee of each participating institution (or an ad hoc ethics committee convened at the request of the principal investigator if the required review process could not be put in place at any of the participating institutions).

: All participants provided written informed consent.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.